50868-74-1

Usage

Uses

Used in Pharmaceutical Industry:
2'-Methyl-3'-methoxyacetanilide is used as an intermediate in the preparation of indole-based derivatives, which act as protecting agents for retinal neuronal cells. These derivatives are valuable in the development of treatments for neurodegenerative diseases affecting the retina, such as age-related macular degeneration and retinitis pigmentosa.
Used in Chemical Synthesis:
2'-Methyl-3'-methoxyacetanilide is also utilized as a building block in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals. Its unique structural features make it a versatile component in the creation of new molecules with potential applications in various industries.

InChI:InChI=1/C10H13NO2/c1-7-9(11-8(2)12)5-4-6-10(7)13-3/h4-6H,1-3H3,(H,11,12)

Upstream product

• 19500-02-8 2-methyl-3-methoxyaniline 
• 108-24-7 acetic anhydride 
• 50868-72-9 5-methoxy-o-toluidine 
• 4837-88-1 6-methoxy-2-nitrotoluene 
• 5460-31-1 3-nitro-o-cresol 

Downstream Products

• 17897-50-6 4-methoxy-2-methylindole 

Relevant academic research and scientific papers

Protective Agent for Retinal Neuronal Cell Comprising Indazole Derivative as Active Ingredient

As a result of intensive studies for the purpose of finding a new medicinal use of an indazole derivative, it was found that an indazole derivative inhibits glutamate-induced retinal neuronal cell death in rat fetal retinal neuronal cells, in other words, the indazole derivative acts directly on the retinal neuronal cells and exhibits an effect of protecting retinal neuronal cells. Accordingly, the indazole derivative is useful for the prevention or treatment of an eye disease associated with retinal neuronal cell damage or retinal damage.

PIPERIDINYLHYDROXYETHYLPIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTORS

The present invention relates to a compound of the formula (I), or a pharmaceutically acceptable salt thereof, wherein R1-R8 and X, m, and n are defined. Compounds and compositions of the present invention are useful the treatment of atherosclerosis.

Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators

Pharmacokinetic studies in cynomolgus monkeys with a novel prototype selective androgen receptor modulator revealed trace amounts of an aniline fragment released through hydrolytic metabolism. This aniline fragment was determined to be mutagenic in an Ames assay. Subsequent concurrent optimization for target activity and avoidance of mutagenicity led to the identification of a pharmacologically superior clinical candidate without mutagenic potential.

NOVEL INDAZOLE DERIVATIVE

An object of the present invention is to create a novel indazole derivative useful as a drug and to find a novel pharmacological action of the derivative. The compound of the present invention is represented by the formula [I] and has an excellent Rho kinase inhibiting action. In the formula, a ring X is a benzene ring or a pyridine ring; R1 and R2 are H or alkyl; R3 and R4 are halogen, H, OH, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, aryloxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, carboxy, hydrocarbonyl, alkylcarbonyl, etc.; and R5 is halogen atom, H, OH, alkoxy, aryloxy, alkyl or aryl. Each group can be substituted.